SymBio Pharmaceuticals Limited Logo

SymBio Pharmaceuticals Limited

Develops and commercializes drugs for oncology, hematology, and rare diseases.

4582 | T

Overview

Corporate Details

ISIN(s):
JP3383050006
LEI:
Country:
Japan
Address:
港区虎ノ門四丁目1番28号

Description

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development and commercialization of new drug candidates. The company's business model involves acquiring development and marketing rights for promising pharmaceuticals from other bio-ventures and pharmaceutical firms to address unmet medical needs. Its core therapeutic areas include oncology, hematology, and rare diseases. A key product in its portfolio is bendamustine hydrochloride (Treakisym), an agent used in the treatment of hematologic cancers such as low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio aims to deliver innovative treatments to patients by advancing its pipeline of specialized drugs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2023-11-14 08:43
確認書
Japanese ZIP 9.2 KB
2023-11-14 08:42
四半期報告書-第19期第3四半期(2023/07/01-2023/09/30)
Japanese ZIP 213.2 KB
2023-08-04 08:38
確認書
Japanese ZIP 9.0 KB
2023-08-04 08:27
四半期報告書-第19期第2四半期(2023/04/01-2023/06/30)
Japanese ZIP 251.9 KB
2023-04-28 08:39
確認書
Japanese ZIP 9.0 KB
2023-04-28 08:36
四半期報告書-第19期第1四半期(2023/01/01-2023/03/31)
Japanese ZIP 185.3 KB
2023-03-24 09:03
確認書
Japanese ZIP 9.0 KB
2023-03-24 08:59
訂正有価証券報告書-第18期(2022/01/01-2022/12/31)
Japanese ZIP 850.7 KB
2023-03-23 08:20
確認書
Japanese ZIP 9.0 KB
2023-03-23 08:18
内部統制報告書-第18期(2022/01/01-2022/12/31)
Japanese ZIP 24.0 KB
2023-03-23 08:13
有価証券報告書-第18期(2022/01/01-2022/12/31)
Japanese ZIP 1.6 MB
2022-11-09 07:59
確認書
Japanese ZIP 9.0 KB
2022-11-09 07:58
四半期報告書-第18期第3四半期(令和4年7月1日-令和4年9月30日)
Japanese ZIP 185.2 KB
2022-08-05 08:15
四半期報告書-第18期第2四半期(令和4年4月1日-令和4年6月30日)
Japanese ZIP 274.3 KB
2022-08-05 08:07
確認書
Japanese ZIP 9.0 KB

Automate Your Workflow. Get a real-time feed of all SymBio Pharmaceuticals Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SymBio Pharmaceuticals Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SymBio Pharmaceuticals Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.